ArticleJCO clinical cancer informatics2025
Linear Federated Learning for Outcome Prediction With Application to Hepatocellular Carcinoma Radiotherapy.
Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeFederated learning (FL) enables multi-institutional predictive modeling without sharing raw patient data, preserving privacy while leveraging diverse data sets. This study evaluates the use of linear FL (LFL) as an interpretable approach to enhance sample size and generalizability in outcome prediction. As a proof of concept, we applied LFL to patients with hepatocellular carcinoma (HCC) undergoing external beam radiotherapy (EBRT), predicting hepatic toxicity and 1-year survival (SRVy1).
methodsPatient data from Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH) were used to train models, whereas an independent validation data set from MD Anderson Cancer Center assessed generalizability. Logistic regression was developed to predict hepatic toxicity and SRVy1 using key clinical features, including baseline albumin, bilirubin, Child-Pugh score, liver size, and mean liver dose. The LFL approach allowed each institution to train models locally without sharing raw patient data. Model performance was evaluated using the AUC and compared between the LFL model and institution-specific models.
resultsFor survival prediction, single-institution models were limited, with AUC = 0.55-0.63, with LFL increasing it to 0.67. For toxicity prediction, external validation showed AUC = 0.68 for the MGH model and 0.69 for the BWH model, with LFL maintaining the AUC at 0.7. The model coefficients were moderate in the LFL compared with the single-institution models, indicating an ability to mitigate bias, which was also reflected by better performance on the validation data set.
conclusionLFL maintained or improved predictive performance over single-institution models for survival and hepatic toxicity in patients with HCC treated with EBRT while preserving model interpretability and patient privacy. These findings support LFL's role in multi-institutional collaborations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.